Eshelman Innovation

What Eshelman Innovation does

Eshelman Innovation is a non-profit healthcare innovation institute embedded within the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, established in 2014 through a $100 million gift from serial entrepreneur Dr. Fred Eshelman. The institute operates two core programs: the Therapeutics Accelerator, which provides strategic funding, translational support, and infrastructure (including the Drug Discovery Initiative's CRISPR screening facility, the HitGen DNA-Encoded Library collaboration, and Triangle CERSI's FDA regulatory science partnership) to advance academic discoveries toward preclinical and early development stages; and the Venture Studio, which conceives, de-risks, and launches digital health startup companies through structured 13-week sprints and the AI-native Kairos platform powered by Amazon Web Services. The portfolio includes therapeutic ventures such as READDI (broad-spectrum antivirals for pandemic preparedness), translational research programs in autoimmune disease, pain, and radiopharmaceuticals, and digital health startups including Goldie Health (overdose prevention), Valable (recovery-friendly workplaces), Kudo Health (rural pharmacy enablement), and TerraLink (hospital wellness). Revenue is sourced from philanthropic gifts, federal grants (notably a $50M FDA award for Triangle CERSI and a $65M NIH NIAID award for READDI), and corporate partnerships, with the institute reporting $268M in follow-on funding generated from $35M of the original Eshelman donation (a 1:8 leverage ratio) and nearly 200 projects funded across UNC-Chapel Hill since 2015. The institute is governed as an academic unit rather than an independent commercial entity, and operates from Chapel Hill with additional venture studio operations in Charlotte in partnership with Atrium Health.

Name

Eshelman Innovation

Legal name

Eshelman Innovation

Website

https://eshelmaninnovation.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Eshelman Innovation is a UNC-Chapel Hill non-profit healthcare innovation institute that funds and translates academic discoveries into therapeutics and digital health startups through its Therapeutics Accelerator and Venture Studio programs.

Ownership category

akta.pro rank

Product category

Healthcare Innovation and Biotech Venture Creation

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512), Pharmaceutical and Medicine Manufacturing (32541), Software Publishers (5132)

SIC

Services-Management Consulting Services (8742), Services-Computer Programming Services (7371), Pharmaceutical Preparations (2834)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

akta.pro secondary industries

Health Informatics & Digital Health Programs (EDAHAGAJ), Innovation & Design Thinking Programs (EDAMAHAD), Innovation Leadership & Leading Growth (EDABAAAO)

Keywords

• Drug discovery
• Biotech venture studio
• Therapeutics accelerator
• Healthcare innovation
• Philanthropic funding

Headquarters

HQ city

Chapel Hill

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Philanthropic Funding: Donations and philanthropic contributions to support healthcare innovation engine operations and research funding. Fred Eshelman provided initial $100 million gift that established the institute.
2. Follow-on Investment Returns: Return on investment from funded projects and startups. Generated $268 million in follow-on funding from $35 million of Dr. Fred Eshelman's donation (a 1:8 return ratio).
3. Venture Fund Investment: First In Venture Fund with High Alpha Innovation allows investors to explore investing in aligned pre-seed fund.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Eshelman Innovation is a non-profit healthcare innovation engine that operates a Therapeutics Accelerator to advance academic discoveries toward clinical development and a Venture Studio (Kairos) that uses AI to create and incubate new healthcare companies. It identifies, funds, and commercializes early-stage therapeutics and digital health ventures, primarily sourced from the UNC Eshelman School of Pharmacy and broader academic network.

Product overview

Eshelman Innovation is a healthcare innovation engine with two core programs: the Therapeutics Accelerator and the Venture Studio. The Therapeutics Accelerator provides strategic funding and translational support for drug discovery through portfolio brands including READDI (pandemic antivirals), Drug Discovery Initiative (CRISPR and DEL screening), Triangle CERSI (FDA regulatory science), and Autoimmune Disease Grants. The Venture Studio builds digital health startups through Kairos (AI-powered venture studio) and portfolio companies including Goldie Health (overdose prevention), Valable (recovery workplace), Kudo Health (rural pharmacy), and TerraLink (hospital wellness). The organization leverages AWS cloud infrastructure and AI tools to accelerate innovation from academia to commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Therapeutics Accelerator: Strategic funding and translational initiatives that de-risk cutting-edge innovations and move assets from discovery to preclinical and early development studies
• Venture Studio
• READDI
• Drug Discovery Initiative (DDI)
• Triangle CERSI
• Kairos
• Goldie Health
• Valable
• Kudo Health
• TerraLink
• Translational Academy
• Rankin Innovator Awards

Products and services

• Therapeutics Accelerator

Quantifiable outcome

• 1:8 return ratio on initial $35M donation
• +3 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature5 records

Partnerships

20 partnerships are on record, tiered core and supporting.

• Amazon Web Services (AWS)coreTechnology or Integration · 1 January 2024AWS is the foundational cloud and AI partner for Kairos venture studio. Provides venture teams with cloud infrastructure, advanced AI/ML services, and technical expertise. Venture Builders receive immersive training, one-on-one mentorship from AWS startup specialists, and credits to build and scale on the AWS platform.
• High Alpha InnovationcoreStrategic or Co-development Partner · 1 January 2021Partnership to create and support digital health startups through venture studio model. Provides venture building expertise, mentorship, and operational support for sprint programs. First In Venture Fund co-investment opportunity.
• MAHEC (Mountain Area Health Education Center)coreStrategic or Co-development PartnerCollaboration for opioid epidemic digital health solutions sprint. MAHEC provides clinical expertise and community connections for Goldie Health platform development and pilot programs.
• Alloy PartnerscoreStrategic or Co-development PartnerVenture innovation partners for studio sprints. Provides startup expertise and pitch day event support. Collaborated on multiple sprints including opioid crisis and Asheville-based programs.
• Orange Grove BiocoreStrategic or Co-development PartnerBiopharmaceutical company-creation firm partnering with university researchers. Co-sponsored autoimmune therapies summit and invests in translational research with commercial potential.
• HBCU Founders InitiativecoreStrategic or Co-development PartnerNational nonprofit partnership to decrease wealth gap by empowering HBCU innovators. Co-sponsors PowerUp and TerraLink initiatives targeting underrepresented communities.
• FDA (Food and Drug Administration)coreStrategic or Co-development Partner$50M CERSI grant awarded to UNC and Duke for regulatory science and innovation center. Triangle CERSI provides regulatory science collaborations and tools for drug development.
• Duke UniversitycoreStrategic or Co-development PartnerPrimary university partner for Triangle CERSI and regulatory science collaboration. Combined expertise across Research Triangle institutions.
• NC State (North Carolina State University)supportingStrategic or Co-development PartnerCollaborating institution for Triangle CERSI regulatory science center. Contributes broad capabilities to FDA partnerships.
• NC Central UniversitysupportingStrategic or Co-development PartnerHistorically Black university collaborating on Triangle CERSI and food insecurity initiatives. Partnered on NCCU design thinking workshops.
• HitGencoreTechnology or IntegrationDNA-Encoded Library company providing no-cost access to screening of billions of small molecule compounds in exchange for IP sharing. Fee-for-service option also available.
• UNC HealthcoreStrategic or Co-development PartnerHealthcare system partner for venture studio digital health ideas and clinical validation support.
• NC A&T (North Carolina A&T State University)coreStrategic or Co-development PartnerHBCU partner for PowerUp nutrition and mental health pitch competition and design thinking workshops.
• Atrium HealthcoreStrategic or Co-development PartnerHealthcare system partner for Charlotte-based Kairos venture studio sprints. Provides clinical expertise and market context for digital health ventures.
• Alexandria Real EstatesupportingStrategic or Co-development PartnerReal estate partner co-hosting Autoimmune Summit for therapeutics curation strategy.
• International Pandemic Preparedness SecretariatcoreStrategic or Co-development PartnerREADDI is core implementation partner in G7 100 Days Mission for pandemic preparedness. Shapes global strategy around broad-spectrum therapeutics development.
• Structural Genomics ConsortiumcoreStrategic or Co-development PartnerREADDI development partner providing structural biology expertise for antiviral drug development.
• OIC Rocky MountsupportingStrategic or Co-development PartnerOpportunities Industrialization Center partnership for PTSD therapy sprint focused on underserved communities.
• UNC Lineberger Comprehensive Cancer CentercoreStrategic or Co-development PartnerStrategic research partnership for radiopharmaceuticals and cancer therapeutics development. DDI development partner.
• Aston UniversitysupportingStrategic or Co-development PartnerInternational research collaboration for CNS edema therapeutic development, three-year project on preventing swelling damage.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Johns Hopkins Technology Ventures (JHTV): Johns Hopkins' technology transfer and startup creation office; comparable as a leading research-university innovation engine with significant healthcare and biotech output.
• Penn Center for Innovation: University of Pennsylvania's technology transfer and commercialization hub; comparable as a top-tier academic innovation engine, though broader (covers all UPenn disciplines, not only healthcare).
• MIT Technology Licensing Office / MIT linQ: MIT's central tech transfer and innovation catalyst organization; broader in scope than Eshelman but operates a similar academic-to-commercial translation model across therapeutics and digital health.

Regional players

• BARDA (Biomedical Advanced Research and Development Authority): U.S. federal agency within HHS that funds advanced development of medical countermeasures; a parallel funder/partner for pandemic preparedness and therapeutic development, comparable in mandate if not in structure.

Direct peers

• Redesign Health: Healthcare-focused venture studio that conceives, launches, and operates digital health companies; directly comparable as both an academic-adjacent and standalone health venture studio with overlapping portfolio themes (digital health, care delivery).
• High Alpha Innovation: Operates a venture studio model focused on building B2B SaaS and vertical SaaS startups; directly partnered with Eshelman Innovation for digital health sprints and shares the same playbook (sprint-based ideation, studio launch, follow-on fund).
• Orange Grove Bio: Biopharmaceutical company-creation firm partnering with university researchers to launch newcos; directly partnered with Eshelman on the autoimmune summit and translational research commercialization.
• Stanford SPARK (SPARK Translational Research Program): University-based translational research program at Stanford that funds and de-risks academic drug discovery projects; highly comparable as a model for moving university science toward commercialization, though at much larger scale.
• Alloy Partners: Venture studio firm specializing in healthcare and life sciences venture creation; collaborates with Eshelman on multiple sprints and is one of the most direct comparables on studio design and process.

Emerging players

• CEPI (Coalition for Epidemic Preparedness Innovations): Global nonprofit funding development of vaccines and therapeutics against epidemic threats; READDI is a core implementation partner, and CEPI's mission directly overlaps READDI's pandemic antiviral mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eshelman-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eshelman Innovation